Renal Function Evolution and Hypoaldosteronism Risk After Unilateral Adrenalectomy for Primary Aldosteronism

 

 Permissions and Reprints

Abstract

Few studies demonstrated a percentage decrease in the estimated glomerular filtration rate (eGFR) at a single time and the rate of hypoaldosteronism after adrenalectomy for primary aldosteronism (PA). Our aim was to investigate the evolution of renal function and the hypoaldosteronism risk after adrenalectomy for PA. Aldosterone, renin, eGFR, and electrolyte levels were determined before and at 1 week, 1, 3 and 6 months after unilateral adrenalectomy in 94 PA patients (40 men and 54 women). The main outcome was the postoperative eGFR decline using analysis of covariance with the preoperative eGFR as a covariate. eGFR decreased during first postoperative week compared to 3 months before surgery. During the first 6 months, eGFR remained stable at similar levels to the first week after surgery. Age (p=0.001), aldosterone levels (p=0.021) and eGFR 3 months before surgery (p+<+0.0001) had a significant correlation with eGFR during first postoperative week. High aldosterone levels at diagnosis were correlated with decline in renal function in the univariate model (p=0.033). In the multivariate analysis, aldosterone levels at diagnosis had a tendency to be an independent predictor of renal function after surgery (p=0.059). Postoperative biochemical hypoaldosteronism was diagnosed in 48% of the cases after adrenalectomy, but prolonged hyperkalemia occurred in only 4 cases (4.5%). Our findings showed a decrease of eGFR after unilateral adrenalectomy for PA. Additionally, aldosterone levels at diagnosis correlated with postoperative renal function. Postoperative biochemical hypoaldosteronism occurred in almost half of the patients, but prolonged hyperkalemia with fludrocortisone replacement was less frequent.

Publication History

Received: 30 July 2023

Accepted after revision: 01 December 2023

Accepted Manuscript online:
01 December 2023

Article published online:
22 January 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Murray CJL, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013; 369: 448-457
  CrossrefPubMedGoogle Scholar
• 2 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
  CrossrefPubMedGoogle Scholar
• 3 Vaidya A, Hundemer GL, Nanba K. et al. Primary aldosteronism: state-of-the-art review. Am J Hypertens 2022; 35: 967-988
  CrossrefPubMedGoogle Scholar
• 4 Vilela LAP, Almeida MQ. Diagnosis and management of primary aldosteronism. Arch Endocrinol Metab 2017; 61: 305-312
  CrossrefPubMedGoogle Scholar
• 5 Brown JM, Siddiqui M, Calhoun DA. et al. The unrecognized prevalence of primary aldosteronism. Ann Intern Med 2020; 173: 10-20
  CrossrefPubMedGoogle Scholar
• 6 Vilela LAP, Rassi-Cruz M, Guimaraes AG. et al. KCNJ5 somatic mutation is a predictor of hypertension remission after adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab 2019; 104: 4695-4702
  CrossrefPubMedGoogle Scholar
• 7 Sukor N, Kogovsek C, Gordon RD. et al. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab 2010; 95: 1360-1364
  CrossrefPubMedGoogle Scholar
• 8 Rossi GP, Cesari M, Cuspidi C. et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertens Dallas Tex 1979 2013; 62: 62-69
  PubMedGoogle Scholar
• 9 Monticone S, D’Ascenzo F, Moretti C. et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018; 6: 41-50
  CrossrefPubMedGoogle Scholar
• 10 Ohno Y, Sone M, Inagaki N. et al. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan. Hypertens Dallas Tex 1979 2018; 71: 530-537
  PubMedGoogle Scholar
• 11 Blasi ER, Rocha R, Rudolph AE. et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-1800
  CrossrefPubMedGoogle Scholar
• 12 Reincke M, Rump LC, Quinkler M. et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab 2009; 94: 869-875
  CrossrefPubMedGoogle Scholar
• 13 Kawashima A, Sone M, Inagaki N. et al. Renal impairment is closely associated with plasma aldosterone concentration in patients with primary aldosteronism. Eur J Endocrinol 2019; 181: 339-350
  CrossrefPubMedGoogle Scholar
• 14 Lu Y-C, Liu K-L, Wu V-C. et al. Factors associated with renal function change after unilateral adrenalectomy in patients with primary aldosteronism. Int J Urol Off J Jpn Urol Assoc 2022; 29: 831-837
  PubMedGoogle Scholar
• 15 Onohara T, Takagi T, Yoshida K. et al. Assessment of postoperative renal function after adrenalectomy in patients with primary aldosteronism. Int J Urol Off J Jpn Urol Assoc 2019; 26: 229-233
  PubMedGoogle Scholar
• 16 Kramers BJ, Kramers C, Lenders JWM. et al. Effects of Treating Primary Aldosteronism on Renal Function. J Clin Hypertens Greenwich Conn 2017; 19: 290-295
  CrossrefPubMedGoogle Scholar
• 17 Kobayashi H, Abe M, Nakamura Y. et al. Association between acute fall in estimated glomerular filtration rate after treatment for primary aldosteronism and long-term decline in renal function. Hypertens Dallas Tex 1979 2019; 74: 630-638
  PubMedGoogle Scholar
• 18 Starker LF, Christakis I, Julien JS. et al. Considering postoperative functional hypoaldosteronism after unilateral adrenalectomy. Am Surg 2017; 83: 598-604
  CrossrefPubMedGoogle Scholar
• 19 Fischer E, Hanslik G, Pallauf A. et al. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy. J Clin Endocrinol Metab 2012; 97: 3965-3973
  CrossrefPubMedGoogle Scholar
• 20 Park KS, Kim JH, Ku EJ. et al. Clinical risk factors of postoperative hyperkalemia after adrenalectomy in patients with aldosterone-producing adenoma. Eur J Endocrinol 2015; 172: 725-731
  CrossrefPubMedGoogle Scholar
• 21 Wada N, Baba S, Sugawara H. et al. Prolonged postoperative hypoaldosteronism related to hyperkalemia in patients with aldosterone-producing adenoma. Endocr J 2023; 70: 917-924
  CrossrefPubMedGoogle Scholar
• 22 Coresh J, Auguste P. Reliability of GFR formulas based on serum creatinine, with special reference to the MDRD Study equation. Scand J Clin Lab Investig Suppl 2008; 241: 30-38
  CrossrefPubMedGoogle Scholar
• 23 Maciel AAW, Freitas TC, Fagundes GFC. et al. Intra-individual variability of serum aldosterone and implications for primary aldosteronism Screening. J Clin Endocrinol Metab 2023; 108: 1143-1153
  CrossrefPubMedGoogle Scholar
• 24 Freitas TC, Maciel AAW, Fagundes GFC. et al. Efficacy of oral furosemide test for primary aldosteronism diagnosis. J Endocr Soc 2023; 8: bvad147
  CrossrefPubMedGoogle Scholar
• 25 Lim V, Guo Q, Grant CS. et al. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism. J Clin Endocrinol Metab 2014; 99: 2712-2719
  CrossrefPubMedGoogle Scholar
• 26 Rassi-Cruz M, Maria AG, Faucz FR. et al. Phosphodiesterase 2A and 3B variants are associated with primary aldosteronism. Endocr Relat Cancer 2021; 28: 1-13
  CrossrefPubMedGoogle Scholar
• 27 Williams B, Mancia G, Spiering W. et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021-3104
  CrossrefPubMedGoogle Scholar
• 28 Malachias MVB, Gomes MAM, Nobre F. et al. 7th Brazilian guideline of arterial hypertension: Chapter 2 - diagnosis and classification. Arq Bras Cardiol 2016; 107: 7-13
  PubMedGoogle Scholar
• 29 Williams TA, Lenders JWM, Mulatero P. et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017; 5: 689-699
  CrossrefPubMedGoogle Scholar
• 30 Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Med Res Methodol 2001; 1: 6
  CrossrefPubMedGoogle Scholar
• 31 van Buuren S. Flexible imputation of missing data, Second Edition. 2nd ed. New York: Chapman and Hall/CRC,; 2018
  CrossrefGoogle Scholar
• 32 Mermejo LM, Elias PCL, Molina CAF. et al. Early renin recovery after adrenalectomy in aldosterone-producing adenomas: a prospective study. Horm Metab Res 2022; 54: 224-231
  Article in Thieme ConnectPubMedGoogle Scholar